Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis
Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy
Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World
CO154 Ramucirumab+Docetaxel Post Immune Checkpoint Inhibitors (ICIS) and Platinum-Based Chemotherapy (CHEMO) in Advanced or Metastatic Non-Small Cell Lung Cancer (ANSCLC): Learnings from the Treat-Lung Observational Study
P1182: REAL-WORLD CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSE/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WHO RECEIVED CAR-T THERAPY
Agreement Between Real-World Physician Response Assessment & the 2017 European Leukemianet (ELN) Criteria in Acute Myeloid Leukemia (AML): A Comparative Analysis
Real-world evaluation of the treatment landscape for chronic lymphocytic leukemia
Development of an Inclusive Risk Prognostic Index for Newly Diagnosed Multiple Myeloma
Identification of Barriers of CAR-T Utilization in Patients with Diffuse Large B-Cell Lymphoma
Frontline Venetoclax (ven) Based Combination Therapy in Older Adults with Acute Myeloid Leukemia Treated in the Real-World Setting; A Multi-Institutional Retrospective Study
